Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(21)00494-0
PubMed Identifier: 34672961
Publication URI: http://europepmc.org/abstract/MED/34672961
Type: Journal Article/Review
Volume: 22
Parent Publication: The Lancet. Oncology
Issue: 11
ISSN: 1470-2045